Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roche nets $1.89bn in Genentech offering

Executive Summary

One month after buying out Genentech, Roche brought the company to the marketplace in an IPO consisting of 20mm common shares at $97 apiece, netting a total of about $1.89bn. The offering, the largest the biotech industry has seen, also includes a 2mm-share underwriter option, and represents roughly 16% of Roche's total Genentech holdings, leaving Roche with post-IPO ownership of 83%.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO
    • Spin-Off

Related Companies